SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle's stock is trending due to a significant after-hours drop following its earnings report, despite an EPS beat, as revenue concerns and increased capital expenditures spooked investors. The community is actively discussing the implications of the results on Oracle's debt and future growth, particularly in the AI space, with some questioning the company's long-term viability while others see a buying opportunity amidst the volatility.

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

BBGI is trending due to a massive intraday surge, sparking discussions about potential short squeezes and after-hours momentum. The stock's volatile price action and frequent trading halts have captivated community attention, with some comparing it to previous high-flying, low-float stocks. Traders are actively debating whether to hold overnight for further gains or take profits amidst the volatility.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amidst a potential bidding war for Warner Bros. Discovery (WBD), with community discussions focused on whether Netflix will increase its offer or walk away; a Paramount bid could allow Netflix to collect a termination fee. Some investors worry about the debt Netflix would incur if it wins the bidding war, while others speculate about political motivations affecting the deal.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending as investors discuss the company's upcoming earnings report and its potential in the AI landscape. While some express concerns about competition from AI and other platforms, others highlight Adobe's established position and potential for growth, emphasizing its AI integration and buyback program.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

Mawson Infrastructure Group ($MIGI) is trending due to increasing interest in its infrastructure growth and expansion into AI and GPU services, differentiating it from typical miners. Community members are actively discussing the stock's low float and potential for a significant short squeeze, with some eyeing price targets between $12 and $40 if catalysts emerge. Traders are also anticipating potential news from an upcoming conference presentation.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station ($GEMI) is trending following the approval of a Designated Contract Market (DCM) license from the CFTC, allowing it to launch prediction markets. The community is discussing the potential for a short squeeze and comparing Gemini's prospects to other players in the prediction market space. Some investors see this as a bullish catalyst, while others express skepticism given GEMI's performance since its IPO.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences is trending due to a U.S. patent allowance for its EVM301 series, sparking discussions of a potential short squeeze given the stock's low float; community members are weighing the IP news against the company's history of dilution. Some traders are also speculating about a potential settlement with AbbVie, which could boost the stock.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the following segments: Design Automation, Design IP, and Software Integrity. The Design Automation segment includes silicon design, verification products and services, system integration products and services, digital, custom, and FPGA IC design software, verification software and hardware products, and manufacturing software products. The Software Integrity segment includes a solution for building security and compliance testing into the customers' software development lifecycle and supply chain. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys Inc

Synopsys ($SNPS) is trending after a significant investment from Nvidia, fueling optimism around AI-driven chip design and engineering; the community is closely watching whether this partnership marks a turning point for the stock, which experienced a notable drop after its recent earnings report, and many are hoping this investment will lead to new all-time highs. Some investors are also closely monitoring the impact of potential restrictions on semiconductor software exports to China, a key market for Synopsys.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recent $20 million investment agreement, sparking significant community discussion about its potential impact and speculation of a short squeeze given the stock's low float. Bullish sentiment is fueled by the anticipation of upcoming news and technical indicators suggesting further upward movement, though some traders caution about potential dilution. The community is actively debating price targets and whether the stock can sustain its gains.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending due to strong earnings, a recent acquisition, and increased price targets from analysts, driving positive after-hours movement. The community is excited about the company's growth, particularly its partnerships and expanding presence in the defense and intelligence sectors. Discussions revolve around the potential for all-time highs and a continued bullish outlook for this space-based data provider.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025

Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025 Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging...

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and...

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy...

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical...

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting...

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements PR Newswire NEW YORK, Jan. 24, 2025 NEW YORK, Jan. 24, 2025...

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent...

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 PR Newswire NEW YORK, Jan. 17, 2025 NEW YORK, Jan. 17...

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries PR Newswire NEW YORK, Jan. 8, 2025 The Company affirms...

Hoth Therapeutics Inc., a micro-cap biotech company, saw its stock price surge over 200% on Tuesday to become the top gainer across U.S. exchanges.&nbsp;Trading volume skyrocketed to 665 times its daily average, driven by positive interim data from its Phase 2a trial of HT-001, a therapy targeting skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitors in cancer patients.The trial achieved a 100% success rate for its primary efficacy endpoint, with all patients showing significant improvement in skin toxicities within six weeks.&nbsp;Additionally, 66% of patients reported reduced pain and itching, improving their quality of life without any treatment-related adverse effects, the company said.CEO Robb Knie described the results as a “significant milestone,” emphasizing the potential of HT-001 to alleviate debilitating skin conditions while enabling patients to continue life-saving cancer treatments.D. Boral Capital echoed this optimism, highlighting the therapy’s potential to revolutionize care for patients enduring severe side effects from cancer treatments.&nbsp;The brokerage reiterated its ‘Buy’ rating and maintained a $5 price target on Hoth’s shares, implying a near doubling from current levels.Retail investors on Stocktwits rallied behind the news, with chatter indicating overwhelmingly bullish commentary.&nbsp;One user predicted a further surge to $10, urging users to “buy cheap now.”&nbsp;<stembedurl>https://stocktwits.com/Aone7Prof/message/599175761</stembedurl>Another emphasized the company’s strong position, pointing out its debt-free status and cash reserves.<stembedurl>https://stocktwits.com/Millionaire2/message/599174136</stembedurl><stembedurl>https://stocktwits.com/JBG99/message/599173146</stembedurl>Hoth’s pipeline includes therapies for dermatological disorders such as eczema, psoriasis, chronic wounds, and acne.&nbsp;The company’s stock has gained nearly 80% over the past year.The successful Phase 2a trial positions Hoth to attract interest from larger players in the oncology and dermatology sectors.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Hoth Therapeutics’ Stock Triples On Promising Cancer Trial Data for Skin Toxicity Therapy: Retail’s Excited 

The trial achieved a 100% success rate for its primary efficacy endpoint, with all patients showing significant improvement in skin toxicities within six weeks.

Equity

The trial achieved a 100% success rate for its primary efficacy endpoint, with all patients showing significant improvement in skin toxicities within six weeks.


Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Hoth Therapeutics Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

HOTH
Hoth Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest HOTH News

HOTHHoth Therapeutics Inc